Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

WHO lists two versions of AstraZeneca/Oxford COVID-19 vaccine for emergency use

Feb. 16, 2021

aTyr Pharma initiates new discovery programs from its tRNA synthetase platform

Feb. 15, 2021

Celon successfully completes phase Ia study of CPL-116

Feb. 12, 2021

FDA clears IND application for INT-301 oral mucosal immunotherapy

Feb. 5, 2021

Multivalent nanobodies potently neutralize SARS-CoV-2 and prevent mutational escape

Feb. 4, 2021

A bivalent measles-based COVID-19 vaccine shows antiviral efficacy in vivo and Th1-biased responses

Feb. 4, 2021

UB-612 multitope peptide-based vaccine against COVID-19 enters phase II trials in Taiwan

Feb. 3, 2021

Kira initiates first-in-human study of P-014 for complement-mediated diseases

Feb. 3, 2021

Clover and Dynavax plan H1 initiation of phase II/III trial of adjuvanted COVID-19 vaccine candidate

Feb. 1, 2021

E.U. grants conditional marketing authorization to AstraZeneca COVID-19 vaccine

Feb. 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...